ArticleIndian journal of urology : IJU : journal of the Urological Society of India
Incidence of adenocarcinoma bladder in patients with cystitis cystica et glandularis: A retrospective study.
Article in Indian journal of urology : IJU : journal of the Urological Society of India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Oral immunosuppression as a bladder-preserving strategy for cystitis cystica et glandularis with intestinal metaplasia.Urology case reports · 2026Article
- Cystitis Cystica et Glandularis: A Dual Case Report and Review of Contemporary Management.Cureus · 2026Article
- Recurrent cystitis glandularis of the bladder: case report and review.Urology case reports · 2026Article
- Personalized prediction for recurrence of cystitis glandularis: insights from SHAP and machine learning models.Translational andrology and urology · 2025Article
- Ureteral reimplantation for the management of pelvic lipomatosis.IJU case reports · 2024Article
- Differences in clinical features between focal and extensive types of cystitis glandularis in patients without a previous history of urinary tract malignancy.Investigative and clinical urology · 2023Article
- Cystitis Cystica Et Glandularis Causing Lower Urinary Tract Symptoms in a 29-Year-Old Male.Cureus · 2021Article
- What's inside.Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCystitis cystica et glandularis (CCG) is a hyper proliferative condition, likely representing a local immune response to chronic inflammatory stimulus. It has been hypothesized as a potential precursor of adenocarcinoma; however, a definite association has not been demonstrated. We aimed to determine whether CCG is a precursor to malignancy and to study the correlation of its two histological variants: the typical and the intestinal metaplasia (IM) type CCG. MATERIALS AND
methodsIn this retrospective study, all the cases of CCG diagnosed and treated between January 2012 and December 2019 were analyzed. All the cases were followed up cystoscopically and biopsies were taken if the lesion persisted. The development of adenocarcinoma during the follow-up was noted. The patients were divided into two groups based on the histological subtype, i.e., the typical type and the IM type, and the two groups were also compared in terms of presentation, cystoscopic appearance, and development of adenocarcinoma.
resultsA total of 64 patients, with 52 in the typical and 12 in the IM group were analyzed. The commonest symptom was hematuria (59.38%), followed by irritative bladder symptoms (51.56%). The median follow-up period was 5 years and 5 months (range: 7-96 months) and no patient progressed to adenocarcinoma. On comparing the two groups, the lesions weresignificantly more extensive in the IM group (50% vs. 15.38%). However, there were no differences in the symptoms or the development of malignancy between the two groups.
conclusionsAt a median of 5 years and 5 months of follow up, CCG (including the IM-type) did not show any increase in the risk of malignancy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.